First Bank & Trust Has $375,000 Stock Holdings in Stevanato Group S.p.A. (NYSE:STVN)

First Bank & Trust cut its holdings in Stevanato Group S.p.A. (NYSE:STVN) by 6.5% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 11,681 shares of the company’s stock after selling 814 shares during the quarter. First Bank & Trust’s holdings in Stevanato Group were worth $375,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of STVN. TimesSquare Capital Management LLC grew its position in shares of Stevanato Group by 64.2% in the 3rd quarter. TimesSquare Capital Management LLC now owns 2,032,361 shares of the company’s stock valued at $60,402,000 after purchasing an additional 794,391 shares during the period. Sands Capital Management LLC boosted its position in Stevanato Group by 46.5% during the 3rd quarter. Sands Capital Management LLC now owns 1,854,880 shares of the company’s stock worth $55,127,000 after acquiring an additional 588,757 shares during the last quarter. Riverbridge Partners LLC boosted its position in Stevanato Group by 78.1% during the 4th quarter. Riverbridge Partners LLC now owns 1,274,805 shares of the company’s stock worth $34,789,000 after acquiring an additional 559,070 shares during the last quarter. Copeland Capital Management LLC boosted its position in Stevanato Group by 18.6% during the 4th quarter. Copeland Capital Management LLC now owns 2,088,778 shares of the company’s stock worth $57,003,000 after acquiring an additional 327,960 shares during the last quarter. Finally, Artisan Partners Limited Partnership boosted its position in Stevanato Group by 63.6% during the 4th quarter. Artisan Partners Limited Partnership now owns 793,000 shares of the company’s stock worth $21,641,000 after acquiring an additional 308,309 shares during the last quarter.

Analysts Set New Price Targets

A number of equities analysts have weighed in on STVN shares. Stephens reaffirmed an “overweight” rating and set a $38.00 price target on shares of Stevanato Group in a research report on Monday, March 25th. BNP Paribas started coverage on Stevanato Group in a research report on Monday, April 22nd. They set an “outperform” rating for the company. Finally, Morgan Stanley reaffirmed an “equal weight” rating and set a $30.00 price target on shares of Stevanato Group in a research report on Monday, April 22nd. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of €34.17 ($36.74).

Stevanato Group Stock Performance

NYSE STVN opened at €18.34 ($19.72) on Friday. The stock has a 50 day moving average of €21.28 and a 200-day moving average of €26.85. Stevanato Group S.p.A. has a 12 month low of €16.56 ($17.81) and a 12 month high of €36.30 ($39.03). The company has a debt-to-equity ratio of 0.21, a current ratio of 1.92 and a quick ratio of 1.35.

Stevanato Group (NYSE:STVN) last posted its quarterly earnings data on Thursday, May 9th. The company reported €0.09 ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of €0.12 ($0.13) by (€0.03) (($0.03)). Stevanato Group had a return on equity of 12.61% and a net margin of 12.57%. The firm had revenue of €256.24 million during the quarter, compared to analysts’ expectations of €261.28 million. As a group, equities analysts expect that Stevanato Group S.p.A. will post 0.54 earnings per share for the current fiscal year.

Stevanato Group Dividend Announcement

The business also recently announced an annual dividend, which will be paid on Monday, July 15th. Investors of record on Tuesday, June 4th will be issued a dividend of $0.053 per share. This represents a yield of 0.29%. The ex-dividend date is Tuesday, June 4th.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.